TNF and Parkinson disease: Rosiglitazone, a glitazone, arrested severe decline of striatal dopamine and partial degeneration of the SNc through reverting PPAR-γ overexpression in microglia, countering the increase in CD11b immunoreactivity, and restoring tumor necrosis factor α (TNF-α) expression down to control levels in a progressive MPTP/probenecid chronic mouse model of PD [128].